These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1487677)

  • 21. From HIV infection to AIDS: a dynamically induced percolation transition?
    Kamp C; Bornholdt S
    Proc Biol Sci; 2002 Oct; 269(1504):2035-40. PubMed ID: 12396503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.
    O'Brien WA; Hartigan PM; Martin D; Esinhart J; Hill A; Benoit S; Rubin M; Simberkoff MS; Hamilton JD
    N Engl J Med; 1996 Feb; 334(7):426-31. PubMed ID: 8552144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group.
    Chaisson RE; Moore RD; Richman DD; Keruly J; Creagh T
    Am Rev Respir Dis; 1992 Aug; 146(2):285-9. PubMed ID: 1362634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
    Justice AC; Stein DS; Fusco GP; Sherrill BH; Fusco JS; Danehower SC; Becker SL; Hansen NI; Graham NM;
    J Clin Epidemiol; 2004 Jan; 57(1):89-97. PubMed ID: 15019015
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Death and HIV infection].
    Van Vooren JP
    Rev Med Brux; 1998 Feb; 19(1):A37-40. PubMed ID: 9553455
    [No Abstract]   [Full Text] [Related]  

  • 26. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex.
    Schmitt FA; Bigley JW; McKinnis R; Logue PE; Evans RW; Drucker JL
    N Engl J Med; 1988 Dec; 319(24):1573-8. PubMed ID: 3059187
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population dynamics of HIV within an individual after treatment with zidovudine.
    McLean AR; Emery VC; Webster A; Griffiths PD
    AIDS; 1991 May; 5(5):485-9. PubMed ID: 1677807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pulmonary function in human immunodeficiency virus infection. A prospective 18-month study of serial lung function in 474 patients.
    Mitchell DM; Fleming J; Pinching AJ; Harris JR; Moss FM; Veale D; Shaw RJ
    Am Rev Respir Dis; 1992 Sep; 146(3):745-51. PubMed ID: 1519857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort.
    Longini IM; Clark WS; Karon JM
    Am J Epidemiol; 1993 Jun; 137(11):1229-40. PubMed ID: 8100682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AZT and asymptomatic HIV infection.
    Van Demark RE
    S D J Med; 1989 Oct; 42(10):9. PubMed ID: 2595355
    [No Abstract]   [Full Text] [Related]  

  • 31. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of AIDS in people with transfusion-acquired HIV infection.
    Kopec-Schrader E; Tindall B; Learmont J; Wylie B; Kaldor JM
    AIDS; 1993 Jul; 7(7):1009-13. PubMed ID: 8357547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Theoretical mechanistic basis of the toxic effects and efficacy of AZT in HIV: AIDS.
    Akintonwa DA
    Med Hypotheses; 2002 Dec; 59(6):622-5. PubMed ID: 12445499
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accommodating change due to treatment in the method of back projection for estimating HIV infection incidence.
    Solomon PJ; Wilson SR
    Biometrics; 1990 Dec; 46(4):1165-70. PubMed ID: 2085631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection.
    Selwyn PA; Alcabes P; Hartel D; Buono D; Schoenbaum EE; Klein RS; Davenny K; Friedland GH
    N Engl J Med; 1992 Dec; 327(24):1697-703. PubMed ID: 1359411
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV infection in recipients of blood products from donors with known duration of infection.
    Ashton LJ; Learmont J; Luo K; Wylie B; Stewart G; Kaldor JM
    Lancet; 1994 Sep; 344(8924):718-20. PubMed ID: 7915778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Median time from seroconversion to AIDS in Italian HIV-positive haemophiliacs: different parametric estimates.
    Chiarotti F; Palombi M; Schinaia N; Ghirardini A; Bellocco R
    Stat Med; 1994 Jan; 13(2):163-75. PubMed ID: 8122052
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early zidovudine and survival in HIV infection. The Veterans Affairs AIDS Cooperative Studies Group.
    Hartigan PM; Hamilton JD; Simberkoff MS
    N Engl J Med; 1992 Sep; 327(11):814-5; author reply 815-6. PubMed ID: 1501668
    [No Abstract]   [Full Text] [Related]  

  • 40. [Zidovudine and human immunodeficiency virus infection: when and how to initiate treatment].
    Corzo JE; Leal M
    Med Clin (Barc); 1991 Jun; 97(5):178-80. PubMed ID: 1921546
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.